- Advanced search
Molecular properties generated using the CDK
|Compound class||Synthetic organic|
|International Nonproprietary Names|
|Example 1 [US20090137530]|
|CAS Registry No.||942399-20-4 (source: WHO INN record)|
|Search Google for chemical match using the InChIKey||JVCPIJKPAKAIIP-UHFFFAOYSA-N|
|Search Google for chemicals with the same backbone||JVCPIJKPAKAIIP|
|Search PubMed clinical trials||amiselimod|
|Search PubMed titles||amiselimod|
|Search PubMed titles/abstracts||amiselimod|
|Amiselimod (MT-1303) is claimed in patent US20090137530 (Compound 1-3 is the hydrochloride used experimentally) as a potential immunomodulatory agent . It is a sphingosine-1-phosphate (SIP) receptor agonist, similar in action to the approved MS drug fingolimod, but with improved receptor subtype selectivity presumed, but note that the selectivity profile of MT-1303 has not been disclosed.
Selective SIP1 receptor agonists are being investigated for immunomodulatory/immunosuppresant action in MS and other autoimmune conditions .